Creatine depletion in the non-viable infarcted human heart was previously demonstrated with proton magnetic resonance (MR) spectroscopy ( 1 H MRS). In the present study, we assessed total creatine (CR) in human hearts with non-ischemic dysfunctions such as cardiomyopathy. Using cardiac-gated 1 H MRS with MR image-guided PRESS localization, we measured septal CR in healthy and diseased human hearts. Fifteen patients with chronic heart failure (CHF, left ventricular ejection fraction º45z) and 14 age-matched normal subjects were examined. Myocardial CR was signiˆcantly (pº0.001) lower in failing hearts (15.1±SD 5.0 mmol W g wet weight, range 8.0-22.9) than in normal hearts (27.6±4.1 mmol W g wet weight, range 20.8-36.2). Myocardial CR concentrations in six heart failure patients with plasma B-type natriuretic peptide (BNP) levels of À200 pg W ml (11.5±0.9 mmol W g wet weight, range 9.9-12.3) were signiˆcantly lower than those in four heart failure patients with plasma BNP levels of º200 pg W ml (19.8±2.5 mmol W g wet weight, range 17.7-22.9, pº0.001). Thus, our study showed that myocardial CR was decreased in non-ischemic dysfunctional hearts. Noninvasive measurements of myocardial CR by 1 H MRS may be useful in the assessment of the severity of heart failure.
Introduction
Recently, total phosphorylated and unphosphorylated creatine (CR) in the human myocardium was noninvasively measured with proton magnetic resonance spectroscopy ( 1 H MRS). 1 H MRS with stimulated-echo acquisition mode (STEAM) localization was used on patients with ischemic heart disease to demonstrate that CR in non-viable infarcted regions was decreased compared with that in non-infarcted regions. 1 The decrease in creatine content measured with 1 H MRS was conˆrmed by biochemical assay at biopsy. 1, 2 These measurements were useful for the assessment of myocardial viability. However, 1 H MRS has not yet been used to fully investigate creatine metabolism in nonischemic dysfunctional hearts.
In the present study, we measured the CR con-centration in human myocardium using cardiacgated 1 H MRS with point-resolved spectroscopy (PRESS) localization. 3 Using 1 H MRS, we compared the myocardial CR concentration in hearts with non-ischemic dysfunctions such as cardiomyopathy with that in healthy controls. We also examined the relationship between the myocardial CR concentration and plasma brain or B-type natriuretic peptide (BNP) level as an indicator of the severity of heart dysfunction. 4, 5 Methods
MRS study
The Ethical Committee of the Shiga University of Medical Science approved the study protocol. MRS studies were conducted with a GE 1.5T Signa imaging W spectroscopy system (General Electric Medical Systems, Milwaukee, WI, USA). Subjects were in the supine position when examined. A Signa 1.5T General Purpose Flex Coil (GPFLEX, Magnetic Resonance in Medical Sciences GE Medical Systems) was wrapped around the chest and centered over the heart. This coil is a receive-only ‰exible coil designed for irregular shapes. It comprises two 13×17 cm loops serially connected to create a corotating``saddle coil'' pair. Cardiac-gated (once per cardiac cycle) spin-echo MR imaging (MRI) was conducted to determine the location of localized volume elements (voxels) for the MRS investigation [echo time (TE), 15 ms; repetition time (TR), 700-1450 ms;ˆeld of view (FOV), 24×24 cm; axial view]. Voxels were localized to 8 cm 3 (2×2×2 cm) in the interventricular septum by the PRESS method. 3 This voxel size was chosen to yield useful signal-to-noise (S W N) ratios. Automatic shimming was performed. The spectral acquisition was gated once per two cardiac cycles with an electrocardiogram or plethysmography. The acquisition parameters were a TE of 25 ms and a TR of 1.4-2.9 s. At the acquisition, the initial data set of 16 signals was collected without water suppression for the water resonance and a data set of 128 signals was collected with water suppression for creatine resonance. The intensity of the tissue water signal from the same voxel was used as an internal concentration reference. 1, 6 A three-pulse chemical-shift-selective sequence was used to suppress the water signal. The chemical shift of water resonance was taken as 4.75 ppm, as indicated in the Signa Horizon LX TM PSD manual. Spectral peaks were identiˆed with the following chemical shifts: cholines at 3.2 ppm, creatine at 3.0 ppm, and lipids at 0.9-1.4 ppm. 1, 3, 7 To conˆrm the accuracy of the localization of selected voxels, we collected spectra from the voxel set within the left ventricular (LV) chamber in some studies, which did not yield a creatine signal.
Preliminary study
Phantom studies were performed prior to the human study. MR spectra were acquired from a bottle containing 10, 20, 30 or 40 mmol W g of creatine placed in a 19-mmol W L NaCl solution. 8 After spin-echo MRI was performed, a voxel (2×2 ×2 cm) was located within the bottle. The MR spectra were acquired with a TE of 25 ms and a TR of 1500 ms.
Quantitative processing
Quantitation of creatine spectra of the myocardium was performed with water signals without suppression as an internal concentration reference. The concentration of total creatine [CR] in the tissueˆlling a voxel was calculated from the tissue water concentration [W] according to the following equation 1, 7 :
Numbers 2 and 3 indicate the two protons of water and the three protons of the N-methyl group of creatine, respectively. SCR and SW are the total creatine and water MR signal areas in the tissue, respectively. Analysis was performed with the simplex technique on a custom-built automatic data processing station. Each peak wasˆtted to an 80z Gaussian and a 20z Lorentzian line. In this study, myocardial tissue water content (55.5 M) was taken as 72.7z by weight: 9, 10 [W] ( mmol W g)＝55.5×0.727×1000 [2] FCRW W and ECRW W are correction factors for T1 and T2 relaxation eŠects, respectively. The T1 values of myocardial CR and W were estimated from the spectra ofˆve healthy volunteers acquired at TRs of 1.5 to 6 s using PRESS without cardiac gating.
The T2 values of myocardial CR and W were obtained from the spectra ofˆve volunteers acquired with TEs of 25-45 ms.
Study group
Fifteen patients, 12 males and 3 females with CHF (LV ejection fraction, EFº45z) in the New York Heart Association (NYHA) functional class II or III (Table 1 ) and 14 age-matched healthy volunteers, 10 males and 4 females, were included in this study. The clinical characteristics are summarized in Table 1 . The averaged period between the onset of the disease and examination by MRS was 75±89 months in 15 patients. There were no signiˆcant diŠerences between the CHF and control groups in terms of age, sex, body weight or heart rate. The NYHA functional class was determined when MRS was performed. Thirteen patients (87z) had a clinical history of severe heart failure (NYHA IV). All patients underwent an MRS study when they were clinically stable. The causes of heart failure were idiopathic dilated cardiomyopathy (DCM) in 11 patients, hypertrophic cardiomyopathy (HCM, dilated phase) in one patient, cardiac amyloidosis in 2 patients, and valvular disease in one patient. Of the patients with CHF, 8 patients (53z) were treated with digitalis, 13 (87z) with diuretics, 13 (87z) with a betablocker, 13 (87z) with angiotensin-converting enzyme (ACE) inhibitor, and 2 (13z) with angiotensin II antagonist. All patients gave their written informed consent before the study.
BNP measurements in patients with CHF
In 10 inpatients with CHF, the plasma BNP levels, which could re‰ect the severity of heart failure, were assessed. The BNP concentrations were measured with a commercially available speciˆc immunoradiometric assay kit for human BNP (Shionoria BNP Kit, Osaka, Japan). Nine of 
Results

Phantom study
Each concentration of creatine was measured twice on the same day to conˆrm reproducibility. The variance between the two measurements was less than 7z. As shown in Fig. 1 , two peaks of creatine were observed at 3.0 (N-CH3) and 3.9 ppm (N-CH2). The ratio of the creatine-to-water MR signal area (SCR W SW) was calculated using a peak of 3.0 ppm. This ratio correlated well with the creatine concentration in the prepared bottle.
MRS study in normal volunteers
Inˆve normal volunteers, the T1 values obtained were 1.48 and 1.21 s (n＝5) for CR and W, respectively, and the T2 values obtained were 135 and 33.1 ms (n＝5) for CR and W, respectively. In the present study, echo time (TE) was set to 25 ms. Therefore, Figure 2 shows the representative cardiac-gated 1 H MRS obtained from a normal volunteer, and Fig. 3 shows that from a patient with CHF. The acquisition time was approximately 5 min per single examination. A reduced CR peak was observed at 3.00±0.06 ppm in CHF. As shown in Fig. 4 , the myocardial CR concentrations in CHF (15.1±5.0 mmol W g wet weight, range 8.0- 22.9) were signiˆcantly (pº0.001 by unpaired ttest) lower than those in normal subjects (27.6± 4.1 mmol W g wet weight, range 20.8-36.2). In addition, the myocardial CR concentration in patients with DCM, who constituted the majority of the CHF group in this study, was 15.0±5.4 mmol W g wet weight. In 10 inpatients with CHF, the plasma BNP levels were measured as an indicator of the severity of CHF. Figure 5 shows the relationship between the plasma BNP level and myocardial CR concentration. Myocardial CR concentrations in heart failure patients who had plasma BNP levels of À200 pg W ml (11.5±0.9 mmol W g wet weight, range 9.9-12.3) were signiˆcantly lower than those in heart failure patients who had plasma BNP levels of º200 pg W ml (19.8±2.5 mmol W g wet weight, range 17.7-22.9, pº0.001).
Discussion
Cardiac-gated 1 H MRS with MRI-guided PRESS localization enabled us to measure myocardial CR quantitatively in humans. Myocardial CR was lower in non-ischemic dysfunctional hearts than in normal hearts. Reduced myocardial CR concentrations were related to the severity of heart failure estimated from the plasma BNP levels.
Metabolic abnormalities in various organs of CHF patients have been reported with MRS. 11, 12 Abnormalities in phosphocreatine (PCr), inorganic phosphate (Pi) and pH in skeletal muscle were previously detected with 31 P MRS. 1 In a recent study using 1 H MRS, creatine depletion in the nonviable infarcted human heart was shown. More recently, metabolic abnormalities of the cerebrum were also reported with 1 H MRS in CHF patients. 6 Thus, previous studies showed the MRS approach was useful in the detection of metabolic changes in various organs in CHF.
In the present study, we used cardiac-gated 1 H MRS with MRI-guided PRESS localization to measure myocardial CR in patients with nonischemic CHF. The myocardial CR in CHF patients was signiˆcantly lower than that in the control subjects. Myocardial CR concentrations in patients who had higher BNP levels were sig-niˆcantly lower than those in patients who had lower BNP levels. Ourˆndings suggest that reduced CR concentrations are associated with the severity of heart failure.
Myocardial energy metabolism is extremely important for the maintenance of normal cardiac function. The dephosphorylation of PCr to unphosphorylated creatine catalyzed by creatine kinase (CK) produces ATP as an essential energy source. ATP is essential to muscle contraction. PCr was previously shown to be the primary highenergy phosphate reservoir in striated muscle. 13 Creatine is not made in the myocardium but is transported from the blood into the myocytes. 14 The CK system plays an important role especially in myocardial energetics during hypoxia 15 or ischemia, 16 since the rate of ATP supply by this system is faster than that from other pathways. 17 It was reported that a decreased energy reserve is closely related to reduced cardiac contractile function in heart failure. 18 In the present study, the voxel was localized to 8 cm 3 (2×2×2 cm) in the interventricular septum with the PRESS method. This size was selected to yield a suitable S W N ratio, but may be somewhat larger than the wall thickness in some cases. The larger space may include the blood of the ventricular cavity. However, spin-echo MRI showed no signal intensity in the chamber. The integrated signal intensity in the larger portion was small owing to the``black blood'' properties of the sequence. 2 Even if the voxel includes a blood space of 30z in total volume, the CR value of 30 mmol W g is underestimated as being 27.6 mmol W g at the most. This diŠerence did not critically aŠect our results.
Our MRS study suggests that myocardial CR is reduced in a variety of failing hearts. As shown in Fig. 3 , reduced CR was observed in DCM patients who constituted the majority of the CHF group in this study. It was previously reported that the myocardial PCr-to-ATP ratio (PCr W ATP) in DCM patients was found to be low with 31 P MRS and that this ratio was related to the severity of heart failure as estimated from the NYHA class 19 and LV systolic function. 20 Thus, the reduced PCr W ATP ratio in DCM may be caused by the reduction of myocardial CR levels, and reduced CR may be attributable to altered kinetics of the membrane-associated speciˆc creatine transport protein. 21 Myocardial CR was markedly reduced in the two cases of cardiac amyloidosis in the present study, whereas myocardial CR was relatively preserved in one case of valvular disease. Because the number of patients studied was very small, however, it was unclear whether this diŠerence is related to a diŠerence in pathology or a diŠerence in the stage of heart disease. Further studies would be needed to elucidate this.
In summary, our study suggests that noninvasive MRS study is useful in the assessment of the severity of disease in dysfunctional hearts.
